Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
7.10.2019 15:30:00 EEST | Business Wire | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.
Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.
“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005221/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Marni Kottle, Media
(650) 522-5388
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arcesium Acquires Limina to Deliver a Unified Front-to-Back Investment Platform2.2.2026 16:00:00 EET | Press release
Arcesium, a leading global financial technology provider to the investment industry, today announces its acquisition of Stockholm-based portfolio and order management (P/OMS) systems provider, Limina, creating a full front-to-back operating platform tailored to the unique needs of asset managers, hedge funds and asset owners. Through the integration of Limina’s P/OMS with Arcesium’s middle- and back-office solutions, the combined offering will be designed to eliminate legacy fragmentation and connect siloed data, providing investment managers with the speed and insight they need to operate intelligently across asset classes and global markets. The entire Limina team will join Arcesium and play a key role in ongoing product development, advancing Arcesium’s commitment to optimizing the pre- and post -investment journey for the world’s most sophisticated financial firms. Limina CEO, Kristoffer Fürst, will join Arcesium, reporting to Arcesium President, Product and Technology, Bryan Dough
KiddeFenwal Launches New Line of Gas Ignition Controls for European and APAC Markets2.2.2026 16:00:00 EET | Press release
KiddeFenwal, the global leader in the fire suppression and safety controls industry, today introduces its 35-2X Series, a new line of direct spark gas ignition controls for original equipment manufacturers (OEMs) in and serving European and Asia-Pacific markets. The series delivers highest quality gas ignition and safety modules supporting 230 VAC applications. The launch marks the next phase of KiddeFenwal’s global growth in the safety controls space, expanding its reach in Europe, Asia and Australia while building on its established North American presence. The company is offering the 35-2X Series via its trusted Fenwal Controls brand, which has served OEMs with reliable products and expert technical advice since 1935. “KiddeFenwal continues to bring new critical control solutions to market, meeting the evolving needs of OEMs and their range of customers worldwide,” said Rekha Agrawal, CEO of KiddeFenwal. “From increasing product complexity to rising energy prices, we deeply understa
Klarna Backs Google’s Universal Commerce Protocol (UCP) to Enable Agentic Commerce Across Platforms2.2.2026 15:30:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, is joining Google's Universal Commerce Protocol (UCP), an open standard designed to help AI agents and commerce systems work together across the full shopping lifecycle, from discovery and purchase through post-purchase support. UCP enables consumers to shop seamlessly in AI conversations while giving agents, merchant systems, and payment providers a standardized way to interact across multiple AI platforms. The announcement builds on Klarna’s recent support for Google’s Agent Payments Protocol (AP2) and expands Klarna's multiyear partnership with Google across Google Pay, Google Store, Google Play, and Google Cloud infrastructure. Together, these efforts reflect ongoing collaboration to support open standards as AI increasingly shapes how consumers shop online. “As AI-driven shopping continues to evolve, it’s important that the underlying commerce infrastructure is built on openness, trust, and transparency,” said David S
Tastepoint by IFF Predicts Ten Flavor Trends for 20262.2.2026 15:15:00 EET | Press release
Tastepoint by IFF (NYSE: IFF), a leader in innovative flavor creations and taste solutions, has identified ten flavors expected to shape the North American food and beverage landscape in 2026. These predictions spotlight flavors anticipated to trend in retail, food service and beyond throughout the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202440399/en/ Flavors featured in Tastepoint by IFF's 2026 trend list. “To continue delivering product development solutions that meet consumers’ unique and changing needs, we stay attuned to industry and market trends, keeping a pulse on what’s relevant now and in the future,” said Nicole Potash, Tastepoint general manager. “Our annual flavor trend predictions reflect a vibrant mix of influences, from nostalgia-driven classics to global favorites gaining momentum in the US, as well as bold new combinations. We hope this year’s list provides brands with valuable insigh
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need2.2.2026 14:30:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that it has entered into a Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic with an initial focus on a gastrointestinal cancer with significant medical need, reflecting AdvanCell’s strategy to build a durable pipeline of differentiated targeted alpha therapies addressing large oncology markets. The collaboration brings together 48Hour Discovery’s peptide discovery platform and AdvanCell’s 212Pb expertise to rapidly construct and advance a peptide-based radiotherapeutic program. Leveraging AdvanCell’s scalable 212Pb platform, which integrates secure isotope supply and modular manufacturing with deep expertise in developing 212Pb radioligand therapies, the program is designed to enable a rapid, repeatable path into the clinic and support the expansion of AdvanCell’s target
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom